These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 7785970)

  • 1. Ribosylation by mycobacterial strains as a new mechanism of rifampin inactivation.
    Dabbs ER; Yazawa K; Mikami Y; Miyaji M; Morisaki N; Iwasaki S; Furihata K
    Antimicrob Agents Chemother; 1995 Apr; 39(4):1007-9. PubMed ID: 7785970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure determination of ribosylated rifampicin and its derivative: new inactivated metabolites of rifampicin by mycobacterial strains.
    Morisaki N; Kobayashi H; Iwasaki S; Furihata K; Dabbs ER; Yazawa K; Mikami Y
    J Antibiot (Tokyo); 1995 Nov; 48(11):1299-303. PubMed ID: 8557572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of rifampin by Nocardia brasiliensis.
    Yazawa K; Mikami Y; Maeda A; Akao M; Morisaki N; Iwasaki S
    Antimicrob Agents Chemother; 1993 Jun; 37(6):1313-7. PubMed ID: 8328779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivated products of rifampicin by pathogenic Nocardia spp.: structures of glycosylated and phosphorylated metabolites of rifampicin and 3-formylrifamycin SV.
    Morisaki N; Iwasaki S; Yazawa K; Mikami Y; Maeda A
    J Antibiot (Tokyo); 1993 Oct; 46(10):1605-10. PubMed ID: 8244890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and characterization of a new intermediate in the ribosylative inactivation pathway of rifampin by Mycobacterium smegmatis.
    Imai T; Watanabe K; Mikami Y; Yazawa K; Ando A; Nagata Y; Morisaki N; Hashimoto Y; Furihata K; Dabbs ER
    Microb Drug Resist; 1999; 5(4):259-64. PubMed ID: 10647083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ADP-ribosylation as an intermediate step in inactivation of rifampin by a mycobacterial gene.
    Quan S; Imai T; Mikami Y; Yazawa K; Dabbs ER; Morisaki N; Iwasaki S; Hashimoto Y; Furihata K
    Antimicrob Agents Chemother; 1999 Jan; 43(1):181-4. PubMed ID: 9869590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphorylative inactivation of rifampicin by Nocardia otitidiscaviarum.
    Yazawa K; Mikami Y; Maeda A; Morisaki N; Iwasaki S
    J Antimicrob Chemother; 1994 Jun; 33(6):1127-35. PubMed ID: 7928806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structures of ADP-ribosylated rifampicin and its metabolite: intermediates of rifampicin-ribosylation by Mycobacterium smegmatis DSM43756.
    Morisaki N; Hashimoto Y; Furihata K; Imai T; Watanabe K; Mikami Y; Yazawa K; Ando A; Nagata Y; Dabbs ER
    J Antibiot (Tokyo); 2000 Mar; 53(3):269-75. PubMed ID: 10819298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Light inhibits rifampicin inactivation and reduces rifampicin resistance due to a cloned mycobacterial ADP-ribosylation gene.
    Dabbs ER; Quan S
    FEMS Microbiol Lett; 2000 Jan; 182(1):105-9. PubMed ID: 10612740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Permeability barrier to rifampin in mycobacteria.
    Hui J; Gordon N; Kajioka R
    Antimicrob Agents Chemother; 1977 May; 11(5):773-9. PubMed ID: 879732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of rifamycin SV and rifampin kinetics in lactating ewes.
    Ziv G; Sulman FG
    Antimicrob Agents Chemother; 1974 Feb; 5(2):139-42. PubMed ID: 4857860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Similar effect of rifampin and other rifamycin derivatives on vaccinia virus morphogenesis.
    Grimley PM; Moss B
    J Virol; 1971 Aug; 8(2):225-31. PubMed ID: 4107245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro susceptibility of Mycobacterium avium complex and Mycobacterium tuberculosis strains to a spiro-piperidyl rifamycin.
    Woodley CL; Kilburn JO
    Am Rev Respir Dis; 1982 Sep; 126(3):586-7. PubMed ID: 6289711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on distribution of dimethylhydrazone of 3-formyl rifamycin SV, a new antibiotic substance.
    Schiatti P; Maffii G
    Chemotherapy; 1967; 12(4):234-46. PubMed ID: 6065357
    [No Abstract]   [Full Text] [Related]  

  • 15. The activity in vitro of Rifamycin SV on various mycobacterial strains including tubercle bacilli isolated from patients never treated with Rifamycin SV.
    Tan THIAM HOK ; The KIE SENG ; Tan LIOE SAN ; Yang SHE YEN ; Widodo S
    Paediatr Indones; 1965; 5(1-2):12-4. PubMed ID: 4959746
    [No Abstract]   [Full Text] [Related]  

  • 16. Different rifampicin inactivation mechanisms in Nocardia and related taxa.
    Tanaka Y; Yazawa K; Dabbs ER; Nishikawa K; Komaki H; Mikami Y; Miyaji M; Morisaki N; Iwasaki S
    Microbiol Immunol; 1996; 40(1):1-4. PubMed ID: 8871521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New C25 carbamate rifamycin derivatives are resistant to inactivation by ADP-ribosyl transferases.
    Combrink KD; Denton DA; Harran S; Ma Z; Chapo K; Yan D; Bonventre E; Roche ED; Doyle TB; Robertson GT; Lynch AS
    Bioorg Med Chem Lett; 2007 Jan; 17(2):522-6. PubMed ID: 17070048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First studies on foetal organotropism of cephalosporin, streptomycin and rifamycin SV under physiological conditions.
    Mascherpa P; Berté F
    Biochem Pharmacol; 1966 Feb; 15(2):200-4. PubMed ID: 5949663
    [No Abstract]   [Full Text] [Related]  

  • 19. Accumulation of rifampicin by Mycobacterium aurum, Mycobacterium smegmatis and Mycobacterium tuberculosis.
    Piddock LJ; Williams KJ; Ricci V
    J Antimicrob Chemother; 2000 Feb; 45(2):159-65. PubMed ID: 10660497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver.
    Vavricka SR; Van Montfoort J; Ha HR; Meier PJ; Fattinger K
    Hepatology; 2002 Jul; 36(1):164-72. PubMed ID: 12085361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.